The Europe 3D bioprinting market is predicted to be worth USD 649.91 million by 2028 and growing at a promising CAGR during the forecast period owing to the increasing focus on health and wellness, increased cosmetic surgery, and agreements between the market key players. As a result, market players in the European region focus on partnerships, alliances, and new products to increase their market presence.
Increasing innovative technology that may imitate the natural tissues with decreasing ownership cost of the equipment is driving the European 3D bioprinting market. The growth is driven by factors like advanced technologies in 3D bioprinters and biomaterials, increasing usage of this type of printing in pharmaceuticals and cosmetology industries, and the rise in public and private funding for supporting bioprinting research activities.
The market players who cause these factors improve and strengthen their manufacturing and distribution capabilities, especially in existing markets, which are regarded to drive market growth. In addition, cells of the same type are also used for a wide range of printing of various bones and tissues, which adapt quickly to growth factors and develop 3D structures.
The factors hampering the European 3D bioprinting market growth are sources of biomaterials used for developing 3D bio-printed products and concerns related to waste elimination.
The rise in demand for organ transplantation, significant mergers and acquisitions to enhance market share, and the expiry of essential patents that offer growth opportunities for existing market players and new entrants create growth potential for the 3D bioprinting market in Europe.
The biggest challenge faced by the 3D bioprinting market in Europe is the usage of multiple technologies, and the increase in demand for highly skilled professionals to handle operations and troubleshoot activities during the 3D bioprinting process makes use of stem cells for the development of products.
Strict regulations related to bioprinting market technology would be a significant challenge for the local market.
This research report on the European 3D Bioprinting Market is segmented & sub-segmented into material type, technologies, components, applications, and country.
By Component:
By Application:
By End User:
By Country:
This 3D bioprinting in medical applications has led to the development of featuring new methods and efficient products. Germany, Switzerland, the UK, and other nations are the pioneers in the Europe 3D bioprinting market. The increasing investments by the public and private sectors and rising healthcare expenses provide immense opportunities for business growth in this vicinity.
KEY MARKET PLAYERS:
Companies like 3Dynamic Systems Ltd., Organovo Holdings, Inc., CELLINK, Bio3D Technologies, Advanced Solutions, Inc., EnvisionTEC GmbH, Ourobotics, 3D Bioprinting Solutions, BioBots, Inc., Poietis, Cyfuse Biomedical K.K., Aerotech, Inc., GeSIM, Nano3D Biosciences, Inc., regenHU Ltd, and GeSIM are playing a leading role in the Europe 3D Bioprinting Market.
Frequently Asked Questions
The European 3D bioprinting market size is predicted to be valued at USD 650 million by 2027.
High cost of 3D bioprinting technology and products, regulatory hurdles, and the lack of standardization in the field are some of the major challenges to the European 3D bioprinting market.
Organovo Holdings Inc., CELLINK AB, regenHU Ltd., Materialise NV, and EnvisionTEC GmbH are some of the notable companies in the European 3D bioprinting market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region